A Case of Metastatic Adamantinoma That Responded Well to Sunitinib

Abstract EN

Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin.

Metastatic adamantinoma has been reported to be resistant to chemotherapy.

We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass.

The patient received radiation therapy to the lung with partial response.

A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma.

He received carboplatin and etoposide for 7 months and achieved a partial response.

Four months later, PET scan showed disease progression.

We started him on sunitinib, a multikinase inhibitor.

He achieved a good partial response for 3 years.

He died due to pneumonia at the age of 72.